Something's got to give

Psychiatric disease on the rise and novel drug development on the decline

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Research and development of drugs for psychiatric disease is currently in a state of decline. Despite the increasing prevalence and healthcare costs of psychiatric disease, the costly and unpredictable drug development process has led to decreased public and investor confidence in the abilities of companies to develop safe and efficacious drugs. Industrial research in this disease area is therefore being scaled back owing to various scientific, corporate, financial and legal factors. This review will consider how these factors contribute to the current status of psychiatric drug development and offer several avenues forward to spur reinvestment in this type of research. Such a shift is needed to reduce the burden psychiatric disease imposes on the healthcare system and its patient populations.

Original languageEnglish (US)
Pages (from-to)202-206
Number of pages5
JournalDrug Discovery Today
Volume18
Issue number3-4
DOIs
StatePublished - Feb 1 2013
Externally publishedYes

Fingerprint

Psychiatry
Pharmaceutical Preparations
Research
Cost of Illness
Health Care Costs
Delivery of Health Care
Population

All Science Journal Classification (ASJC) codes

  • Drug Discovery
  • Pharmacology

Cite this

@article{e025a54c3d6a4caa8da944dc322149de,
title = "Something's got to give: Psychiatric disease on the rise and novel drug development on the decline",
abstract = "Research and development of drugs for psychiatric disease is currently in a state of decline. Despite the increasing prevalence and healthcare costs of psychiatric disease, the costly and unpredictable drug development process has led to decreased public and investor confidence in the abilities of companies to develop safe and efficacious drugs. Industrial research in this disease area is therefore being scaled back owing to various scientific, corporate, financial and legal factors. This review will consider how these factors contribute to the current status of psychiatric drug development and offer several avenues forward to spur reinvestment in this type of research. Such a shift is needed to reduce the burden psychiatric disease imposes on the healthcare system and its patient populations.",
author = "Daniel Chandler",
year = "2013",
month = "2",
day = "1",
doi = "https://doi.org/10.1016/j.drudis.2012.08.003",
language = "English (US)",
volume = "18",
pages = "202--206",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier Limited",
number = "3-4",

}

Something's got to give : Psychiatric disease on the rise and novel drug development on the decline. / Chandler, Daniel.

In: Drug Discovery Today, Vol. 18, No. 3-4, 01.02.2013, p. 202-206.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Something's got to give

T2 - Psychiatric disease on the rise and novel drug development on the decline

AU - Chandler, Daniel

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Research and development of drugs for psychiatric disease is currently in a state of decline. Despite the increasing prevalence and healthcare costs of psychiatric disease, the costly and unpredictable drug development process has led to decreased public and investor confidence in the abilities of companies to develop safe and efficacious drugs. Industrial research in this disease area is therefore being scaled back owing to various scientific, corporate, financial and legal factors. This review will consider how these factors contribute to the current status of psychiatric drug development and offer several avenues forward to spur reinvestment in this type of research. Such a shift is needed to reduce the burden psychiatric disease imposes on the healthcare system and its patient populations.

AB - Research and development of drugs for psychiatric disease is currently in a state of decline. Despite the increasing prevalence and healthcare costs of psychiatric disease, the costly and unpredictable drug development process has led to decreased public and investor confidence in the abilities of companies to develop safe and efficacious drugs. Industrial research in this disease area is therefore being scaled back owing to various scientific, corporate, financial and legal factors. This review will consider how these factors contribute to the current status of psychiatric drug development and offer several avenues forward to spur reinvestment in this type of research. Such a shift is needed to reduce the burden psychiatric disease imposes on the healthcare system and its patient populations.

UR - http://www.scopus.com/inward/record.url?scp=84873095820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873095820&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.drudis.2012.08.003

DO - https://doi.org/10.1016/j.drudis.2012.08.003

M3 - Review article

VL - 18

SP - 202

EP - 206

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

IS - 3-4

ER -